Cystic fibrosis (CF) is an autosomal recessive disorder with an incidence of approximately 1 in 2000 live births and a carrier frequency of 1 in 20 (1). The disease locus, initially mapped to 7q31 (2), was recently identified as a gene spanning 250 000 base pairs (bp) that codes for a protein of 1480 amino acids (3). Approximately 70% of CF mutations involve a deletion of 3 bp in exon 10, resulting in the loss of a phenylalanine at position 508 in the gene product (4). Because this mutation neither creates nor destroys a restriction enzyme cutting site, it is currently being detected with radiolabeled allele-specific oligonucleotides (4). We report a rapid, nonisotopic technique to detect chromosomes carrying this deletion.
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Genomic DNA is extracted from leukocytes 3'-end of the forward primer overlaps the deletion locus and includes a single-base mismatch designed to alter the sequence of the amplified product (7). The PCR-mediated site-directed mutagenesis gives rise to products carrying a novel restriction site for the enzyme Mall; this restriction site is associated with the wild-type allele but not with the CF mutant allele (Figure 1) .
After amplification, the product is digested with Mnll and electrophoresed on polyacrylaniide.
Healthy, noncarrier individuals exhibit 56-and 30-bp fragments, whereas affected individuals homozygous for this deletion show a single 83-bp fragment, which lacks the Mnll restriction site. Heterozygotes for the deletion exhibit all three bands plus a heteroduplex fragment, formed by the re-annealing of 86-and 83-bp amplification products, migrating at '=100 bp (8). The heteroduplex band serves as a second indicator of heterozygosity and as a control for denoting underdigestion (Figure 2) .
About half of the individuals with CF are homozygous for the phenylalanine deletion. Of the remaining half 80% will be compound heterozygotes between the phenylalanine deletion and less-prevalent mutations. The ability to rapidly detect the deletion in these affected heterozygotes will reduce the dependence on linkage analysis in family studies, although linkage studies will still be required for the families with affected individuals who lack the identified deletion. This test has applicability to prenatal testing, newborn screening, and carrier detection analysis. For use in a clinical context, the sensitivity of PCR analysis necessitates rigorous adherence to procedures that will minimize the possibility of misdiagnoses attributable to contamination (9).
